1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Dr Chris Burns CEO and MD of Amplia Therapeutics (ASX: ATX) shares updates on their ongoing ACCENT trial for pancreatic cancer. The trial shows promise with a recent patient achieving a pathological complete response, emphasising its potential to enhance chemotherapy effectiveness.
Dr Chris highlights the critical need for improved treatments in pancreatic cancer, given the low survival rates. With fast-track designation from the US FDA, Amplia aims for rapid progression, though market approval remains a few years away.
Amplia (ASX: ATX) holds over $10 million for trials, and plans collaboration for further research. Chris hopes for increased investor support, aligning with promising Australian innovation to boost survival rates.
